Clinical Trials at Levine Cancer Institute
As of September 2026, 56 paid clinical trials are recruiting at Levine Cancer Institute, located at Atrium Health Levine Cancer Institute, 1021 Morehead Medical Dr, Charlotte, NC 28204, phone (980) 442-2000 in Charlotte, North Carolina. Active studies at this site cover conditions such as Multiple Myeloma, Breast Cancer and Acute Myeloid Leukemia. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
View the full facility profile →
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Charlotte
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
A Study of ARC-02 in B-cell NHL
58 clinical trials at Levine Cancer Institute
·Clear filters·A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
Study of SGR-3515 In Participants With Advanced Solid Tumors.
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Common conditions studied in Charlotte
- Multiple Myeloma (13 active studies)
- Breast Cancer (11 active studies)
- Acute Myeloid Leukemia (10 active studies)
- Heart Failure (8 active studies)
- Obesity (7 active studies)
- Sickle Cell Disease (7 active studies)
Leading research sponsors in Charlotte
- Wake Forest University Health Sciences
- National Cancer Institute (NCI)
- AstraZeneca
- Janssen Research & Development, LLC
- Merck Sharp & Dohme LLC
Frequently asked questions
How many paid clinical trials are currently recruiting in Charlotte?
There are approximately 512 recruiting clinical trials in Charlotte, North Carolina listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Charlotte pay participants?
Most recruiting trials in Charlotte compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Charlotte?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Charlotte?
The most common conditions under active study in Charlotte include Multiple Myeloma (13), Breast Cancer (11), Acute Myeloid Leukemia (10), Heart Failure (8), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Charlotte?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Charlotte on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Charlotte?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Charlotte?
Recruiting research sites in Charlotte include Levine Cancer Institute, Carolinas Medical Center/Levine Cancer Institute, Atrium Health, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Charlotte right now?
The largest active categories in Charlotte are Cancer & tumors (178), Neurology & pain (32), Cardiovascular (24). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Levine Cancer Institute?
Levine Cancer Institute is located at Atrium Health Levine Cancer Institute, 1021 Morehead Medical Dr, Charlotte, NC 28204. Use the Google Maps link in the intro above to get directions.
How do I contact Levine Cancer Institute?
You can reach Levine Cancer Institute by phone at (980) 442-2000. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.